PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers

Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers
2024-04-16
(Press-News.org) Building on the anti-tumor potential of Polθ inhibition in BRCA-deficient cancers, researchers at Insilico Medicine discovered a new class of orally bioavailable Polθ inhibitors designed using generative AI. For molecular generation, they used both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies within the Chemistry42 generative chemistry engine. The new inhibitors demonstrated strong potency and promising druglike properties, highlighting AI’s potential in medicinal chemistry for precise molecular modifications. A crucial player in genomic integrity maintenance, DNA Polymerase Theta (Polθ) provides a potential synthetic lethal relationship in BRCA-deficient tumors, which are particularly prevalent in certain tumor types including triple-negative breast cancers (TNBC) and ovarian cancers. In fact, BRCA-deficient tumors account for 11-16% of TNBC cases, and 10-15% of ovarian cancers. Given limited treatment options and compromised efficacy due to resistance, alternative treatment strategies including Polθ inhibitors are urgently needed.

Now, researchers from Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, have discovered a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, the Company’s proprietary generative AI platform. According to the findings, the AI-enabled molecules exhibited significant enzymatic and cellular potency and promising druglike properties, pointing to a novel strategy for targeting Polθ. The research was published in Bioorganic & Medicinal Chemistry, an Elsevier peer-reviewed journal focusing on molecular chemistry and biology.

Aiming for a novel and potent Polθ inhibitor with new cores, the Insilico R&D team implemented both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies. Based on novel central scaffold rings innovated with the help of Chemistry42, a promising lead compound was identified, and further optimization for improved potency and other druglike properties yielded 3-hydroxymethyl-azetidine derivatives as a novel class of Polθ inhibitors.

In consequent validation, a novel compound exhibited robust cellular potency in DNA repair-compromised cells, as well as favorable ADME profiles and pharmacokinetic properties in vivo. This orally bioavailable molecule shows potential as a possible treatment approach for solid cancers with BRCA1/2 mutations, and the findings demonstrate the potential of using AI in medicinal chemistry for precise molecular modifications.

Insilico Medicine is a pioneer in utilizing generative AI for drug discovery and development, and has delivered breakthroughs for healthcare in multiple disease areas, including fibrosis, cancer, immunology and aging-related diseases. Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets and has advanced six pipelines to the clinical stage. Most recently, the company published a history of its lead AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis, currently in Phase II clinical trials, in Nature Biotechnology.

 

 About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com

END

[Attachments] See images for this press release:
Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers 2 Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers 3

ELSE PRESS RELEASES FROM THIS DATE:

New A.I. project will allow industrial robots to be more freethinking

2024-04-16
Robots are increasingly being used in industry, and in future they will need to adapt to unforeseen events and changes in their environment much more than today, including when they work with humans. A new international research project is addressing this issue using artificial intelligence. The project is being funded by Horizon Europe, the EU framework programme for research and innovation, with a grant of DKK 56 million (EUR 7.5 million) and is called RoboSapiens (Robotic Safe Adaptation In Unprecedented Situations). The RoboSapiens project will reduce ...

Computer scientist William Wang receives prestigious early career technical achievement award

Computer scientist William Wang receives prestigious early career technical achievement award
2024-04-16
(Santa Barbara, Calif.) — As artificial intelligence continues to boom, scaling algorithms to ever-increasing data sets also becomes a bigger hurdle. Such is the case in the domain of natural language processing (NLP), or, the effort to get machines to understand and communicate with human language (think: ChatGPT, search engines and other text-based modalities). “A key challenge in this domain is the tradeoff between scalability and accuracy,” said UC Santa Barbara computer scientist ...

UC Irvine researchers shine light on rapid changes in Arctic and boreal ecosystems

2024-04-16
Irvine, Calif., April 16, 2024 — Arctic and boreal latitudes are warming faster than any other region on Earth. In three new studies, Earth system scientists at the University of California, Irvine report how the ecosystems in these regions are changing.   In a study published in Global Change Biology, a team led by Earth system science Ph.D. candidate Jinhyuk Kim from the lab of James Randerson, professor of Earth system science, reveals how wildfires are increasing rates of photosynthesis in Canada and Alaska.    They find that increasing wildfires are wiping out black spruce forests that grow relatively slowly and contribute to the organic layer of the underlying ...

Trash to treasure – researchers turn metal waste into catalyst for hydrogen

Trash to treasure – researchers turn metal waste into catalyst for hydrogen
2024-04-16
Scientists have found a way to transform metal waste into a highly efficient catalyst to make hydrogen from water, a discovery that could make hydrogen production more sustainable. A team of researchers from the University of Nottingham's School of Chemistry and Faculty of Engineering have found that the surface of swarf, a byproduct of the metal machining industry, is textured with tiny steps and grooves on a nanoscale level. These textures can anchor atoms of platinum or cobalt, leading to an efficient electrocatalyst ...

Microplastics, algal blooms, seafood safety are public health concerns addressed by new Oceans and Human Health Centers

2024-04-16
For Immediate Release April 16, 2024 Microplastics, algal blooms, seafood safety are public health concerns addressed by new Oceans and Human Health Centers    NIH and NSF jointly fund new research centers to better understand how ocean-related exposures affect people’s health.  To address plastics and other problems that could affect human health, the NIH and the U.S. National Science Foundation (NSF) are jointly funding four new Centers for Oceans and Human Health and renewing two centers as part of a marine-related health research program. Each Center will focus on a different aspect ...

Alba Yerro-Colom to use National Science Foundation CAREER award to better predict and prevent landslides

2024-04-16
Almost one-fifth of the global land surface is classified as highly susceptible to rainfall-triggered landslides. According to the World Health Organization, landslides are more widespread than any other geological hazard to occur worldwide and are increasing because of climate change.  Alba Yerro-Colom, assistant professor in the Charles E. Via, Jr. Department of Civil and Environmental Engineering, is motivated to advance the understanding of these natural occurrences while considering how vegetation and changes in rainfall patterns could better predict their potential damage. She ...

Researchers discover urine-based test to detect head and neck cancer

2024-04-16
Researchers from the University of Michigan Health Rogel Cancer Center have created a urine-based test that detects pieces of DNA fragments released by head and neck tumors. The test could potentially facilitate early detection of this cancer type, which currently does not have a reliable screening method. Human papillomavirus (HPV) is widely recognized for causing cervical cancer, but is increasingly found to cause cancers in the mouth, throat and other head and neck regions. Early detection is critical because detecting a cancer at ...

Moffitt treats first clinical trial patient with gamma delta CAR T for bone metastatic prostate cancer

2024-04-16
TAMPA, Fla. — Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop bone metastases. The disease significantly impacts patients, causing extreme bone pain. The CAR T-cell therapy, developed in the lab of Moffitt immunologist Daniel Abate-Daga, PhD, utilizes gamma delta T cells to target a tumor biomarker highly expressed in bone metastatic prostate cancer called prostate stem cell antigen. ...

Wiley's latest natural products database release empowers drug discovery and research

Wileys latest natural products database release empowers drug discovery and research
2024-04-16
 Wiley, one of the world’s largest publishers and a global leader in research and learning, today announced the 2024 release of its Wiley Identifier of Natural Products (AntiBase Library + ChemWindow). With an extensive collection of over 95,000 compounds, this growing natural products database serves as a powerful drug discovery screening tool to narrow down possible novel compounds having antimicrobial, antitumor, or other desired effects. Additionally, it finds applications in food and cosmetics, agriculture, pesticides, and ...

Reproductive success improves after a single generation in the wild for descendants of some hatchery-origin Chinook salmon

2024-04-16
NEWPORT, Ore. – Researchers who created “family trees” for nearly 10,000 fish found that first-generation, wild-born descendants of hatchery-origin Chinook salmon in an Oregon river show improved fitness. The finding, based on data collected over 13 years, is encouraging for Chinook salmon recovery efforts, said Kathleen O’Malley, an associate professor at Oregon State University and the study’s senior author. In this study, fitness is measured by the number of adult offspring a fish produces, with higher fitness leading to more offspring. “Previous studies have shown that hatchery-origin Chinook salmon have lower reproductive success ...

LAST 30 PRESS RELEASES:

Political elites take advantage of anti-partisan protests to disrupt politics

Tiny target discovered on RNA to short-circuit inflammation, UC Santa Cruz researchers find

Charge your laptop in a minute? Supercapacitors can help; new research offers clues

Scientists discover CO2 and CO ices in outskirts of solar system

Theory and experiment combine to shine a new light on proton spin

PKMYT1, a potential ‘Achilles heel’ of treatment resistant ER+ breast cancers with the poorest prognosis

PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors (PARs)

Virginia Tech researcher creates new tool to move tiny bioparticles

On repeat: Biologists observe recurring evolutionary changes, over time, in stick insects

Understanding a broken heart

Genetic cause of rare childhood immune disorders discovered

With wobbling stars, astronomers gauge mass of 126 exoplanets and find 15 new ones

High H5N1 influenza levels found in mice given raw milk from infected dairy cows

Study finds discreet shipping used to sell e-cigarettes to minors

African scientists call for equitable research partnerships to advance microbiome research

How COVID-19 'breakthrough' infections alter your immune cells

Virginia Tech entomologist sheds light on 250-year-old mystery of the German cockroach

Advancing skin science: explore Skin Ageing & Challenges 2024 Strategic Topics in Malta this November

Controlling water, transforming greenhouse gases

MSK Research Highlights, May 24, 2024

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

ASCO: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Euclid space mission releases first scientific results and new images of the cosmos

Sociodemographic heterogeneity in the associations of social isolation with mortality

COVID-19 admission rates and changes in care quality in us hospitals

Preterm and early-term delivery after heat waves in 50 US metropolitan areas

Research spotlight: Virtual scribes reduced physicians’ time spent on electronic health records

Duke-NUS researchers develop new light-controlled ‘off switch’ for brain cells

Liver lesions at risk of transformation into hepatocellular carcinoma in cirrhotic patients

Update on the STING signaling pathway in developing nonalcoholic fatty liver disease

[Press-News.org] Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers